Skip to main content
. 2021 Nov 9;43(7):1793–1802. doi: 10.1038/s41401-021-00782-6

Fig. 6. CDDO-Im exerts chondroprotective effects by activating Nrf2.

Fig. 6

a Representative Western blot of Nrf2, Collagen II, Aggrecan, MMP13, Adamts5, cleaved caspase 3, Bax and Bcl-2 in chondrocytes pretreated with CDDO-Im (20 nM) with or without TNF-α (50 ng/mL) in the presence or absence of ML385 (20 μM) for 24 h. b Quantitative analysis of the protein levels in Fig. 6a. c Western blot analysis of Nrf2 protein expression in chondrocytes treated with three siRNAs. d Quantitative analysis of the protein levels in Fig. 6c. e Representative Western blotting of Collagen II, Aggrecan, MMP13, Adamts5, cleaved caspase 3, Bax and Bcl-2 in chondrocytes pretreated with CDDO-Im (20 nM) with or without TNF-α (50 ng/mL) in the presence or absence of siN2 for 24 h. f Quantitative analysis of the protein levels in Fig. 6e. The values are presented as the means ± SDs. *P < 0.05 versus control, #P < 0.05 versus TNF-α-treated chondrocytes, †P < 0.05 versus TNF-α- and CDDO-Im-treated chondrocytes.